Skip to Content
Merck
  • HT update: spotlight on estradiol/norethindrone acetate combination therapy.

HT update: spotlight on estradiol/norethindrone acetate combination therapy.

Clinical interventions in aging (2008-05-21)
Colleen L Casey, Christine A Murray
ABSTRACT

Abstract: The goal ofpostmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
19-Norethindrone, ≥98%, powder
Norethisterone, European Pharmacopoeia (EP) Reference Standard
USP
Norethindrone, United States Pharmacopeia (USP) Reference Standard
Norethisterone for system suitability, European Pharmacopoeia (EP) Reference Standard